Ushering in a new era of fit-for-purpose clinical endpoints for Rett syndrome
When the strength of a clinical endpoint lies in its design, challenges arise when measures are chosen simply because they…
All articles by Justine Ra
Justine Ra
Justine Ra is a healthcare reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing coverage on neurology and neurodegenerative diseases. Justine holds a degree in English from The University of Michigan, Ann Arbor.
-
-
Alzheimer’s heterogeneity necessitates diverse enrollment in clinical trials
Clinical trials are the final bridge to cross before a new treatment can reach patients. Though Alzheimer's disease affects individuals…
-
Pan Cancer T looks to increase T cell durability with next-gen TCR-T
As it gradually makes its way into clinical stages, Pan Cancer T aims to increase the duration of response of…
-
RegenxBio touts positive data for rare disease drug RGX-121
RegenxBio has announced that the pivotal dose level from its multiphase study of RGX-121 has demonstrated positive long-term data for…
-
DMD clinical studies evolve with emphasis on building designs around relevant endpoints
Though progress is being made in an indication with no known cure and only a handful of treatments, the recent…
-
Pfizer and BioNTech’s Covid-19/flu combination vaccine falters in Phase III readout
Pfizer and BioNTech have announced that a Phase III trial studying their investigational combination mRNA vaccine for the treatment of…
-
Pfizer touts positive topline data for RSV vaccine Abrysvo
Pfizer has announced positive topline results from a pivotal late-stage study of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in…
-
AAIC 2024: Eisai presents positive long-term data with Leqembi
Eisai has announced that patients undergoing continuous treatment with its anti-amyloid therapy Leqembi (lecanemab) for three years have shown a…
-
AAIC 2024: The evolution of Alzheimer’s clinical trials
As the industry paints an increasingly clearer picture for Alzheimer’s disease pathologies, treatments are becoming more inclusive of non-pharmacological lifestyle…
-
Clinical trial diversity is a balancing act of time, quality, and money
While the topic of clinical trial diversity has been in circulation for some time, it has recently gained traction with…